Professional Documents
Culture Documents
Basicpacingconceptsppt2017-171221084227 2
Basicpacingconceptsppt2017-171221084227 2
CONCEPTS
JANUARY 2017
DISCLOSURES
This presentation is provided for general educational purposes only and should not
be considered the exclusive source for this type of information. Patient information
(names, serial numbers, date, etc.) has been changed or removed to protect the
privacy of the patients used in this presentation.
Important Reminder: This information is intended only for users in markets where
Medtronic products and therapies are approved or available for use. Content on
specific Medtronic products and therapies is not intended for users in markets that
do not have authorization for use.
OBJECTIVES
One lead
Atrium
Ventricle (most common)
May be used for patients in chronic
AF (VVI pacemaker) or patients
with sinus node dysfunction and no
history of AV block (AAI
pacemaker)
Two leads
One lead implanted in the atrium
One lead implanted in the
ventricle
Provides AV synchrony and pacing
support in both atrium and
ventricle if needed
DDD Pacemaker
DUAL CHAMBER PACEMAKER
RA Lead in Appendage
Leads or wires
Cathode (negative electrode)
Anode (positive electrode)
Body tissue
Anode
Cathode
THE PULSE GENERATOR
Longevity Battery
Dependent on impedance and
output
Commonly ranges from 6-12
years
LEADS ARE INSULATED WIRES
Lead
LEAD POLARITY
Unipolar leads
May have a smaller diameter
lead body than bipolar leads
May exhibit larger pacing
artifacts on the surface ECG Unipolar lead
May cause pectoral muscle
stimulation
Al-Ahmad, A, Ellenbogen KA, Natale A, Wang PJ. Pacemakers and Implantable Cardioverter Defibrillators: An Expert's Manual. Minneapolis, MN: Cardiotext Publishing;
2010.
UNIPOLAR PACING SYSTEM
Anode
Cathode -
Cathode
TRANSVENOUS LEADS
Hayes, DL, Friedman P. Cardiac Pacing, Defibrillation and Resynchronization: A Clinical Approach. Hoboken, NJ: Wiley-Blackwell Publishing; 2008.
KNOWLEDGE CHECKPOINT
Note: The terms “amplitude” and “voltage” are often used interchangeably in pacing.
INITIAL INTERROGATION REPORT
Note: All clinic, physician, and patient names and data in this document are fictitious
VOLTAGE
CURRENT
Note: One ampere is a unit of electrical current produced by 1 volt acting through a resistance of 1 ohm. 1 Ampere = 1000 milliamps
CURRENT
IMPEDANCE
Note: All clinic, physician, and patient names and data in this document are fictitious
IMPEDANCE
SUMMARY
VOLTAGE, CURRENT, AND IMPEDANCE
Voltage: The force moving the current (V)
In pacemakers it is a function of the battery chemistry
V
V I = V / R
I = R
I R R = V / I
V
I = R
OHM’S LAW TELLS US:
1. If the impedance (R) remains constant, and the voltage decreases, the
current decreases
2. If the voltage is constant, and the impedance decreases, the current
increases
Know where to find the voltage and impedance on the programmer and
report
Ohm’s law and the relationship between voltage, current, and impedance
Knowing how these factors relate to each other can help you
understand how the pacemaker paces the heart
TESTING THE
PACEMAKER
CIRCUIT
TYPICAL LEAD IMPEDANCE RANGE
Most important that lead impedance is stable over the lifetime of the
device.
Hayes, DL, Friedman P. Cardiac Pacing, Defibrillation and Resynchronization: A Clinical Approach. Hoboken, NJ: Wiley-Blackwell Publishing; 2008.
LEAD IMPEDANCE VALUES
ELECTRICAL ANALOGIES
Normal resistance – friction caused by the hose and nozzle
Other reason for high impedance: Lead not seated properly in pacemaker
header (usually an acute problem).
CASE STUDY: CLINIC VISIT
85 year old male with h/o pacemaker implant in 1996. Generator change in
2005. Follow up visits in clinic have been normal. He now comes into your
office complaining of light-headedness and fatigue.
You interrogate his pacemaker and find the ventricular lead impedance is
1,867 ohms and it was usually trending around 700 ohms.
CHEST X RAY
Now that you know what the problem is, How do you fix it?
SOLUTIONS FOR LEAD CRUSH
Lead II
Marker
Channel
V EGM
INSULATION BREAK
Since the lead is still oversensing and has a low impedance in the unipolar
configuration, a lead replacement should be considered.
The compromised lead can be capped and a new ventricular pacing lead
can be placed at least 1 cm away to prevent lead-lead noise.
CAPTURE THRESHOLD
Lead maturation
Fibrotic “capsule” develops around the electrode following lead
implantation
May gradually raise threshold
Usually no measurable effect on impedance
Ellenbogen, KA, Wood MA. Cardiac Pacing and ICDs. Hoboken, NJ: Blackwell Publishing; 2008.
STEROID ELUTING LEADS
Ellenbogen, KA, Wood MA. Cardiac Pacing and ICDs. Hoboken, NJ: Blackwell Publishing; 1996.
FACTORS THAT CAN AFFECT THRESHOLDS
Hayes DL, Asirvatham SJ, Friedman PA. Cardiac Pacing, Defibrillation, and Resynchronization. Hoboken, NJ: Wiley-Blackwell; 2010.
MYOCARDIAL CAPTURE
A patient presented to the ER with the complaint that he felt just the way
he did when he first received his pacemaker. What is your interpretation?
ORDER A CHEST X-RAY
Curtis, AB. Fundamentals of Cardiac Pacing. Sudbury, MA: Jones and Bartlett Publishers; 2010.
SENSITIVITY
LESS SENSITIVE = HIGH SENSITIVITY NUMBER
MORE SENSITIVE = LOW SENSITIVITY NUMBER
ADEQUATE SENSITIVITY
SENSING AMPLIFIERS/FILTERS
Affected by:
Pacemaker circuit (lead) integrity
Insulation break
Wire fracture
The characteristics of the electrode
Electrode placement within the heart
The sensing amplifiers of the pacemaker
Lead polarity (unipolar vs. bipolar)
The electrophysiological properties of the myocardium
EMI – Electromagnetic Interference
UNDERSENSING . . .OVERPACING
Pacemaker does not “see” the intrinsic beat, and therefore does not
respond appropriately
OVERSENSING …UNDERPACING
PACEMAKER A PACEMAKER B
CASE STUDY: TELEMETRY CALL
• The NBG code indicates the pacing mode and whether the pacemaker is
pacing, sensing, and inhibiting in either the atrium and ventricle.
If you are located in the United States, please refer to the brief statement(s) below to review
applicable indications, safety and warning information. See the device manual for detailed
information regarding the implant procedure, indications, contraindications, warnings,
precautions, and potential complications/adverse events. For further information, please call
Medtronic at 1.763.514.4000 and/or consult the Medtronic website at www.medtronic.com.
If you are located outside the United States, see the device manual for detailed information
regarding the implant procedure, indications, contraindications, warnings, precautions, and
potential adverse events. For further information, contact your local Medtronic representative
and/or consult the Medtronic website at www.medtronic.com.
Consult instructions for use at this website. Manuals can be viewed using a current version of any
major Internet browser. For best results, use Adobe Acrobat Reader® with the browser.
BRIEF STATEMENTS (USA): IPGS
Indications
Implantable Pulse Generators (IPGs) are indicated for rate adaptive pacing in patients who may benefit from increased pacing rates concurrent with increases in
activity. Pacemakers are also indicated for dual chamber and atrial tracking modes in patients who may benefit from maintenance of AV synchrony. Dual chamber
modes are specifically indicated for treatment of conduction disorders that require restoration of both rate and AV synchrony, which include various degrees of AV
block to maintain the atrial contribution to cardiac output and VVI intolerance (e.g. pacemaker syndrome) in the presence of persistent sinus rhythm. See device
manuals for the accepted patient conditions warranting chronic cardiac pacing. Antitachycardia pacing (ATP) is indicated for termination of atrial tachyarrythmias in
patients with one or more of the above pacing indications. For the MR Conditional IPGs, a complete SureScan® pacing system, which consists of an approved
combination (see http://www.mrisurescan.com/) MRI SureScan device with SureScan lead(s), is required for use in the MR environment.
Contraindications
IPGs are contraindicated for concomitant implant with another bradycardia device and concomitant implant with an implantable cardioverter defibrillator. There are no
known contraindications for the use of pacing as a therapeutic modality to control heart rate. The patient’s age and medical condition, however, may dictate the
particular pacing system, mode of operation, and implant procedure used by the physician. Rate-responsive modes may be contraindicated in those patients who
cannot tolerate pacing rates above the programmed Lower Rate. Dual chamber sequential pacing is contraindicated in patients with chronic or persistent
supraventricular tachycardias, including atrial fibrillation or flutter. Asynchronous pacing is contraindicated in the presence (or likelihood) of competition between
paced and intrinsic rhythms. Single chamber atrial pacing is contraindicated in patients with an AV conduction disturbance. Anti-tachycardia pacing (ATP) therapy is
contraindicated in patients with an accessory antegrade pathway.
Warnings/Precautions
Changes in a patient’s disease and/or medications may alter the efficacy of the device’s programmed parameters. Patients should avoid sources of magnetic and
electromagnetic radiation to avoid possible underdetection, inappropriate sensing and/or therapy delivery, tissue damage, induction of an arrhythmia, device
electrical reset or device damage. Do not place transthoracic defibrillation paddles directly over the device.
For MR Conditional IPG Systems, before performing an MRI scan, refer to the SureScan pacing system technical manual for additional information, patients and their
implanted systems must be screened to meet the MRI Conditions of Use. Do not scan patients who do not have a complete SureScan pacing system consisting of an
approved combination MRI SureScan device with SureScan lead(s); patients who have broken, abandoned or intermittent leads; or patients who have a lead impedance
value of < 200 Ω or > 1,500 Ω.
Potential complications
Potential complications include, but are not limited to, rejection phenomena, erosion through the skin, muscle or nerve stimulation, oversensing, failure to detect
and/or terminate arrhythmia episodes, and surgical complications such as hematoma, infection, inflammation, and thrombosis.
SureScan systems have been designed to minimize potential complications in the MRI environment. Potential MRI complications include, but are not limited to, lead
electrode heating and tissue damage resulting in loss of sensing or capture or both, or induced currents on leads resulting in continuous capture, VT/VF, and/or
hemodynamic collapse.
See the device manual for detailed information regarding the implant procedure, indications, contraindications, warnings, precautions, and potential
complications/adverse events. For further information, please call Medtronic at 1-800-328-2518 and/or consult Medtronic’s website at www.medtronic.com.
Caution: Federal law (USA) restricts these devices to sale by or on the order of a physician.
AUGUST 25, 2015
BRIEF STATEMENT (USA): CRT PACEMAKERS (IPGS)
Indications
Cardiac Resynchronization Therapy (CRT) IPGs are indicated for NYHA Functional Class III and IV patients who remain symptomatic despite stable, optimal heart
failure medical therapy and have a LVEF ≤ 35% and a prolonged QRS duration and for NYHA Functional Class I, II, or III patients who have a LVEF ≤ 50%, are on stable,
optimal heart failure medical therapy if indicated and have atrioventricular block (AV block) that are expected to require a high percentage of ventricular pacing that
cannot be managed with algorithms to minimize right ventricular pacing. Optimization of heart failure medical therapy that is limited due to AV block or the urgent
need for pacing should be done post implant. Rate adaptive pacing is provided for those patients developing a bradycardia indication who might benefit from increased
pacing rates concurrent with increases in activity. Dual chamber and atrial tracking modes are indicated for patients who may benefit from maintenance of AV
synchrony. Antitachycardia pacing (ATP) is indicated for termination of atrial tachyarrhythmias in patients with one or more of the above pacing indications.
Contraindications
CRT IPGs are contraindicated for concomitant implant with another bradycardia device and concomitant implant with an implantable cardioverter defibrillator. There
are no known contraindications for the use of pacing as a therapeutic modality to control heart rate. The patient’s age and medical condition, however, may dictate the
particular pacing system, mode of operation, and implant procedure used by the physician. Rate-responsive modes may be contraindicated in those patients who
cannot tolerate pacing rates above the programmed Lower Rate. Dual chamber sequential pacing is contraindicated in patients with chronic or persistent
supraventricular tachycardias, including atrial fibrillation or flutter. Asynchronous pacing is contraindicated in the presence (or likelihood) of competition between
paced and intrinsic rhythms. Single chamber atrial pacing is contraindicated in patients with an AV conduction disturbance. Anti-tachycardia pacing (ATP) therapy is
contraindicated in patients with an accessory antegrade pathway.
Warnings/Precautions
Changes in a patient’s disease and/or medications may alter the efficacy of the device’s programmed parameters. Patients should avoid sources of magnetic and
electromagnetic radiation to avoid possible underdetection, inappropriate sensing and/or therapy delivery, tissue damage, induction of an arrhythmia, device
electrical reset or device damage. Do not place transthoracic defibrillation paddles directly over the device.
Additionally, for CRT ICDs and CRT IPGs, certain programming and device operations may not provide cardiac resynchronization. Also for CRT IPGs, Elective
Replacement Indicator (ERI) results in the device switching to VVI pacing at 65 ppm. In this mode, patients may experience loss of cardiac resynchronization therapy
and / or loss of AV synchrony. For this reason, the device should be replaced prior to ERI being set. Use of the device should not change the application of established
anticoagulation protocols.
Potential complications
Potential complications include, but are not limited to, rejection phenomena, erosion through the skin, muscle or nerve stimulation, oversensing, failure to detect
and/or terminate arrhythmia episodes, and surgical complications such as hematoma, infection, inflammation, and thrombosis.
See the device manual for detailed information regarding the implant procedure, indications, contraindications, warnings, precautions, and potential
complications/adverse events. For further information, please call Medtronic at 1-800-328-2518 and/or consult Medtronic’s website at www.medtronic.com.
Caution: Federal law (USA) restricts these devices to sale by or on the order of a physician.
Potential Complications
Potential complications include, but are not limited to, valve damage, fibrillation and other arrhythmias, thrombosis, thrombotic and
air embolism, cardiac perforation, heart wall rupture, cardiac tamponade, muscle or nerve stimulation, pericardial rub, infection,
myocardial irritability, and pneumothorax. Other potential complications related to the lead may include lead dislodgement, lead
conductor fracture, insulation failure, threshold elevation or exit block.
See the device manual for detailed information regarding the implant procedure, indications, contraindications, warnings, precautions,
and potential complications/adverse events. For further information, please call Medtronic at 1-800-328-2518 and/or consult
Medtronic’s website at www.medtronic.com.
Caution: Federal law (USA) restricts this device to sale by or on the order of a physician.
See the device manual for detailed information regarding the implant procedure, indications, contraindications, warnings,
precautions, and potential complications/adverse events. For further information, please call Medtronic at 1-800-328-2518 and/or
consult Medtronic’s website at www.medtronic.com.
Caution: Federal law (USA) restricts these devices to sale by or on the order of a physician.
BRIEF STATEMENTS (USA): ATTAIN® PERFORMA™ 4298
LEAD
Indications
The Attain Performa 4298 steroid eluting, quadripolar electrode, IS4 transvenous lead is indicated for chronic pacing and sensing in the left
ventricle via the cardiac vein, when used with a compatible Medtronic Cardiac Resynchronization Therapy (CRT) system. Extended bipolar
pacing is available using this lead in combination with a compatible CRT-D system and RV defibrillation lead.
Contraindications
Coronary vasculature – This lead is contraindicated for patients with coronary venous vasculature that is inadequate for lead placement, as
indicated by venogram.
Steroid use – Do not use in patients for whom a single dose of 288 μg of dexamethasone acetate may be contraindicated.
Warnings and Precautions
Chronic repositioning or removal of leads may be difficult because of fibrotic tissue development.
Output pulses, especially from unipolar devices, may adversely affect device sensing capabilities. If a patient requires a separate stimulation
device, either permanent or temporary, allow enough space between the leads of the separate systems to avoid interference in the sensing
capabilities of the devices. Previously implanted pulse generators and implantable cardioverter defibrillators should generally be explanted.
People with metal implants such as pacemakers, implantable cardioverter defibrillators (ICDs) and accompanying leads should not receive
diathermy treatment. The interaction between the implant and diathermy can cause tissue damage, fibrillation, or damage to the device
components, which could result in serious injury, loss of therapy, and/or the need to reprogram or replace the device.
Leads should be handled with great care at all times. Use an anchoring sleeve with all leads. Ensure the anchoring sleeve is positioned close to
the lead connector pin, to prevent inadvertent passage of the sleeve into the vein. Use care when handling stylets. Any severe bending
kinking, stretching, handling with surgical instruments, or excessive force when inserting a stylet may cause permanent damage to the lead.
Rust stylets are not recommended with this lead due to the risk of conductor coil or insulation perforation.
Use care when handling guide wires. Damage to the guide wire may prevent the guide wire from performing with accurate torque response
and may cause vessel damage. Do not use excessive force to retract the guide wire from the lead. Refer to the product documentation
packaged with the guide wire for additional information.
Do not use magnetic resonance imaging (MRI) on patients who have this device implanted. MRI can induce currents on implanted leads,
potentially causing tissue damage and the induction of tachyarrhythmias.
BRIEF STATEMENTS (USA): ATTAIN® PERFORMA™ 4298 LEAD
CONTINUED
For the Model 4298 lead, total patient exposure to dexamethasone acetate should be considered. Drug interactions of dexamethasone
acetate with this lead have not been studied. It has not been determined whether the warnings, precautions, or complications usually
associated with injectable dexamethasone acetate apply to the use of this highly localized, controlled-release device. For a list of potential
adverse effects, refer to the Physician’s Desk Reference.
Do not force the guide catheter or leads if significant resistance is encountered. Use of guide catheters and/or leads may cause trauma to the
heart.
Keep external defibrillation equipment nearby for immediate use during acute lead system testing, the implant procedure, or whenever
arrhythmias are possible or intentionally induced during the post-implant testing. Backup pacing should be readily available during implant.
Use of the delivery system or leads may cause heart block.
To minimize the likelihood of trauma to the vein and to maintain lead flexibility while advancing the lead through the vein, keep the stylet
withdrawn 1 to 2 cm or select a more flexible stylet.
Do not insert the proximal end of the guide wire through the lead tip seal without using the guide wire insertion tool. Inserting the guide wire
without the guide wire insertion tool may damage the lead.
During lead implant and testing, use only battery-powered equipment or line-powered equipment specifically designed for this purpose to
protect against fibrillation that may be caused by alternating currents.
Potential Complications
Potential complications related to the use of transvenous leads include, but are not limited to the following patient-related conditions: cardiac
dissection, cardiac perforation, cardiac tamponade, coronary sinus dissection, death, endocarditis, erosion through the skin, extracardiac
muscle or nerve stimulation, fibrillation or other arrhythmias, heart block, heart wall or vein wall rupture, hematoma/seroma, infection,
myocardial irritability, myopotential sensing, pericardial effusion, pericardial rub, pneumothorax, rejection phenomena, threshold elevation,
thrombosis, thrombotic or air embolism, and valve damage.
See the device manual for detailed information regarding the implant procedure, indications, contraindications, warnings, precautions, and potential
complications/adverse events. For further information, please call Medtronic at 1 (800) 723-4636 and/or consult Medtronic’s
website at www.medtronic.com.
Caution: Federal law (USA) restricts these devices to sale by or on the order of a physician.
BRIEF STATEMENT (USA): MEDTRONIC ATTAIN ABILITY
MODEL 4196, ABILITY PLUS MODEL 4296, AND ABILITY
STRAIGHT MODEL 4396 LEADS
Steroid eluting, dual electrode, transvenous, over the wire, cardiac vein pacing leads. The Model 4396 lead has tined fixation.
Indications
The Attain Ability Models 4196, 4296, and 4396 steroid eluting, dual electrode, IS-1 transvenous leads are indicated for chronic pacing and
sensing in the left ventricle via the cardiac vein, when used in conjunction with a compatible Medtronic Cardiac Resynchronization Therapy
(CRT) system. Extended bipolar pacing is available using this lead in combination with a compatible CRT-D system and RV defibrillation lead or
with a compatible CRT-P system and RV pacing lead. Additionally, unipolar pacing is available using the leads in combination with a compatible
CRT-P system.
Contraindications
Coronary vasculature - The leads are contraindicated for patients with coronary venous vasculature that is inadequate for lead placement, as
indicated by venogram.
Steroid use - Do not use in patients for whom a single dose of 232 µg of dexamethasone acetate cannot be tolerated.
Warnings and Precautions
The Model 4196, 4296, and 4396 were designed for optimal pacing when used in a unipolar or extended bipolar configuration. The standard
bipolar configuration may result in markedly elevated pacing thresholds or produce anodal stimulation.
Chronic repositioning or removal of leads may be difficult because of fibrotic tissue development. The clinical studies for these leads were not
designed to evaluate the removal of left ventricular leads from the coronary venous vasculature.
Output pulses, especially from unipolar devices, may adversely affect device sensing capabilities. If a patient requires a separate stimulation
device, either permanent or temporary, allow enough space between the leads of the separate systems to avoid interference in the sensing
capabilities of the devices. Previously implanted pulse generators and implantable cardioverter defibrillators should generally be explanted.
People with metal implants such as pacemakers, implantable cardioverter defibrillators (ICDs) and accompanying leads should not receive
diathermy treatment. The interaction between the implant and diathermy can cause tissue damage, fibrillation, or damage to the device
components, which could result in serious injury, loss of therapy, and/or the need to reprogram or replace the device.
BRIEF STATEMENT (USA): MEDTRONIC ATTAIN ABILITY
MODEL 4196, ABILITY PLUS MODEL 4296, AND ABILITY
STRAIGHT MODEL 4396 LEADS
CONTINUED
Leads should be handled with great care at all times. Use an anchoring sleeve with all leads. Ensure the anchoring sleeve is positioned close to
the lead connector pin, to prevent inadvertent passage of the sleeve into the vein. Use care when handling stylets. Any severe bending
kinking, stretching, handling with surgical instruments, or excessive force when inserting a stylet may cause permanent damage to the lead.
When using Model 4196, 4296, or 4396 leads, only use compatible stylets (stylets with downsized knobs and are 3 cm shorter than the lead
length). Other stylets may extend beyond the lead tip causing lead tip seal damage or injury or perforation of the cardiac vein or heart. Rust
stylets are not recommended with these leads due to the risk of conductor coil or insulation perforation.
Use care when handling guide wires. Damage to the guide wire may prevent the guide wire from performing accurate torque response control
and may cause vessel damage. Do not use excessive force to retract the guide wire from the lead. Refer to the literature packaged with the
guide wire for additional information on guide wires.
Do not use magnetic resonance imaging (MRI) on patients who have this device implanted. MRI can induce currents on implanted leads,
potentially causing tissue damage and the induction of tachyarrhythmias.
For the Model 4196, 4296, or 4396 leads, total patient exposure to dexamethasone acetate should be considered. Drug interactions of
dexamethasone acetate with this lead have not been studied. It has not been determined whether the warnings, precautions, or
complications usually associated with injectable dexamethasone acetate apply to the use of this highly localized, controlled-release lead. For a
list of potential adverse effects, refer to the Physicians' Desk Reference.
Do not force the guide catheter or leads if significant resistance is encountered. Use of guide catheters and/or leads may cause trauma to the
heart.
Keep external defibrillation equipment nearby for immediate use during acute lead system testing, the implant procedure, or whenever
arrhythmias are possible or intentionally induced during the post-implant testing. Backup pacing should be readily available during implant.
Use of the delivery system or leads may cause heart block.
To minimize the likelihood of trauma to the vein and to maintain lead flexibility while advancing the lead through the vein, keep the stylet
withdrawn 1 to 2 cm or select a more flexible stylet.
Do not insert the proximal end of the guide wire through the lead tip seal without using the guide wire insertion tool. Inserting the guide wire
without the guide wire insertion tool could cause damage to the lead tip seal or to the conductor core or insulation.
BRIEF STATEMENT (USA): MEDTRONIC ATTAIN ABILITY
MODEL 4196, ABILITY PLUS MODEL 4296, AND ABILITY
STRAIGHT MODEL 4396 LEADS
CONTINUED
During lead implant and testing, use only battery-powered equipment or line-powered equipment specifically designed for this purpose to
protect against fibrillation that may be caused by alternating currents.
Potential Complications
Potential complications related to the use of tranvenous leads include, but are not limited to the following patient-related conditions: cardiac
dissection, cardiac perforation, cardiac tamponade, coronary sinus dissection, death, endocarditis, erosion through the skin, extracardiac
muscle or nerve stimulation, fibrillation or other arrhythmias, heart block, heart wall or vein wall rupture, hematoma/seroma, infection,
myocardial irritability, myopotential sensing, pericardial effusion, pericardial rub, pneumothorax, rejection phenomena, threshold elevation,
thrombosis, thrombotic or air embolism, and valve damage.
See the device manual for detailed information regarding the implant procedure, indications, contraindications, warnings, precautions, and potential
complications/adverse events. For further information, please call Medtronic at 1 (800) 328-2518 and/or consult Medtronic’s website
at www.medtronic.com.
Caution: Federal law (USA) restricts these devices to sale by or on the order of a physician.
BRIEF STATEMENT (USA): MEDTRONIC ATTAIN BIPOLAR
OTW MODEL 4194 LEAD
Indications
The Attain Bipolar OTW Model 4194 steroid eluting, IS-1 transvenous lead is indicated for chronic pacing and sensing in the left ventricle via
the cardiac vein, when used in conjunction with a compatible Medtronic Cardiac Resynchronization Therapy (CRT) system. Extended bipolar
pacing is available using this lead in combination with a compatible CRT-D system and RV defibrillation lead or with a compatible CRT-P
system and RV pacing lead.
Contraindications
Coronary vasculature - The leads are contraindicated for patients with coronary venous vasculature that is inadequate for lead placement, as
indicated by venogram.
Steroid use - Do not use steroid eluting leads in patients for whom a single dose of 1.0 mg dexamethasone sodium phosphate cannot be
tolerated.
Warnings/Precautions
The Model 4194 was designed for optimal pacing when used in a bipolar configuration. The standard bipolar configuration may result in
markedly elevated pacing thresholds or produce anodal stimulation.
Chronic repositioning or removal of leads may be difficult because of fibrotic tissue development. The clinical studies were not designed to
evaluate the removal of left ventricular leads from the coronary venous vasculature.
Output pulses, especially from unipolar leads, may adversely affect device sensing capabilities. Previously implanted pulse generators,
implantable cardioverter defibrillators, and leads should generally be explanted.
People with metal implants such as pacemakers, Implantable Cardioverter Defibrillators (ICDs), and accompanying leads should not receive
diathermy treatment. The interaction between the implant and diathermy can cause tissue damage, fibrillation, or damage to the device
components, which could result in serious injury, loss of therapy, and/or the need to reprogram or replace the device.
Leads should be handled with great care at all times. Use an anchoring sleeve with all leads. Ensure the anchoring sleeve is positioned close to
the lead connector pin, to prevent inadvertent passage of the sleeve into the vein. Use care when handling stylets. Any severe bending,
kinking, stretching, handling with surgical instruments, or excessive force when inserting a stylet, may cause permanent damage to the lead.
When using Model 4194 leads, only use compatible stylets (stylets with downsized knobs and are 3 cm shorter than the lead length). Other
stylets may extend beyond the lead tip causing lead tip seal damage or injury, or perforation of the cardiac vein or heart. Rust stylets are not
recommended with this lead due to the risk of conductor coil or insulation perforation.
BRIEF STATEMENT (USA): MEDTRONIC ATTAIN BIPOLAR
OTW MODEL 4194 LEAD
CONTINUED
Use care when handling guide wires. Damage to the guide wire may prevent the guide wire from performing accurate torque response control
and may cause vessel damage. Do not use excessive force to retract the guide wire from the lead. Refer to the literature packaged with the
guide wire for additional information on guide wires.
Do not use Magnetic Resonance Imaging (MRI) on patients who have this device implanted. MRI can induce currents on implanted leads,
potentially causing tissue damage and the induction of tachyarrhythmias.
For the Model 4194 lead, total patient exposure to dexamethasone sodium phosphate should be considered. Drug interactions of
dexamethasone sodium phosphate with this lead have not been studied. It has not been determined if whether the warnings, precautions, or
complications usually associated with injectable dexamethasone sodium phosphate apply to the use of this highly localized, controlled-
release lead. For a list of potential adverse effects, refer to the Physicians' Desk Reference.
Do not force the guide catheter and/or leads if significant resistance is encountered. Use of the guide catheters and/or leads may cause
trauma to the heart.
Keep external defibrillation equipment nearby for immediate use during the acute lead system testing, the implant procedure, or whenever
arrhythmias are possible or intentionally induced during the post-implant testing. Backup pacing should be readily available during implant.
Use of the delivery system or leads may cause heart block.
To minimize the likelihood of trauma to the vein and to maintain lead flexibility while advancing the lead through the vein keep the stylet
withdrawn 1-2 cm or select a more flexible stylet.
Do not insert the proximal end of the guide wire through the lead tip seal without using the guide wire insertion tool. Inserting the guide wire
without the guide wire insertion tool could cause damage to the lead tip seal or to the conductor core or insulation.
During lead implant and testing, use only battery powered equipment or line-powered equipment specifically designed for this purpose to
protect against fibrillation that may be caused by alternating currents.
BRIEF STATEMENT (USA): MEDTRONIC ATTAIN BIPOLAR
OTW MODEL 4194 LEAD
CONTINUED
Potential Complications
Potential complications related to the use of transvenous leads include, but are not limited to the following patient-related conditions: cardiac
dissection, cardiac perforation, cardiac tamponade, coronary sinus dissection, death, endocarditis, erosion through the skin, extracardiac
muscle or nerve stimulation, fibrillation or other arrhythmias, heart block, heart wall or vein wall rupture, hematoma/seroma, infection,
myocardial irritability, myopotential sensing, pericardial effusion, epicardial rub, pneumothorax, rejection phenomena, threshold elevation,
thrombosis, thrombotic or air embolism, and valve damage.
See the device manual for detailed information regarding the implant procedure, indications, contraindications, warnings, precautions, and potential
complications/adverse events. For further information, please call Medtronic at 1-800-328-2518 and/or consult Medtronic’s website
at www.medtronic.com.
Caution: Federal law (USA) restricts these devices to sale by or on the order of a physician.
BRIEF STATEMENT (USA): MEDTRONIC ATTAIN STARFIX
MODEL 4195 LEAD
Indications
The Attain StarFix Model 4195 steroid eluting, transvenous lead with deployable lobes is intended for chronic pacing and sensing of the left
ventricle via a cardiac vein, when used in conjunction with a compatible implantable pulse generator or implantable cardiac defibrillator.
Contraindications
Coronary vasculature - This lead is contraindicated for patients with coronary venous vasculature that is inadequate for lead placement, as
indicated by venogram.
Steroid use - Do not use in patients for whom a single dose of 30 μg (micrograms) of beclomethasone dipropionate (BDP) cannot be tolerated.
Warnings/Precautions
Leads, stylets, and guide wires should be handled with great care at all times. When using the Model 4195 lead, only use compatible stylets
(stylets with downsized knobs and are 3 cm shorter than the lead length). Verify that the stylet does not extend beyond the lead tip prior to
inserting the lead in the delivery system. Implanting the lead with the stylet extending beyond the lead tip could cause injury or perforation of
the cardiac vein or heart.
Output pulses, especially from unipolar leads, may adversely affect device sensing capabilities.
Backup pacing should be readily available during implant. Use of leads may cause heart block.
For the Attain StarFix Model 4195 lead, total patient exposure to beclomethasone 17,21-dipropionate should be considered when implanting
multiple leads. No drug interactions with inhaled beclomethasone 17,21-dipropionate have been described. Drug interactions of
beclomethasone 17,21-dipropionate with the Model 4195 lead have not been studied.
People with metal implants such as pacemakers, implantable cardioverter defibrillators (ICDs), and accompanying leads should not receive
diathermy treatment. The interaction between the implant and diathermy can cause tissue damage, fibrillation, or damage to the device
components, which could result in serious injury, loss of therapy, or the need to reprogram or replace the device.
Do not use magnetic resonance imaging (MRI) on patients who have this device. MRI can induce currents on implanted leads, potentially
causing tissue damage and the induction of tachyarrhythmias.
Always use an acute retention clip to reposition or remove the lead. Always attempt to undeploy the lobes before repositioning or removing
the lead. If a lead must be removed or repositioned, consider referring the case to an experienced extraction center. Do not implant the acute
retention clip.
Previously implanted pulse generators, implantable cardioverter-defibrillators, and leads should generally be explanted.
BRIEF STATEMENT (USA): MEDTRONIC ATTAIN STARFIX
MODEL 4195 LEAD
CONTINUED
Extraction Warning
The risk and difficulty of removing the Medtronic Attain StarFix Model 4195 lead after a long implant time has not been studied. In light of the
novel fixation mechanism of the Model 4195 lead, there may be unique risk and difficulty associated with chronic removal. If a lead must be
removed or repositioned, consider referring the case to an experienced extraction center. Do not implant the acute retention clip.
Potential Complications
Potential clinical complications resulting from the use of transvenous leads include, but are not limited to the following: air embolism, avulsion
of the endocardium, valve, or vein, cardiac dissection, cardiac perforation, cardiac tamponade, coronary sinus dissection, death, endocarditis
and pericarditis, erosion through the skin, extracardiac muscle or nerve stimulation, fibrillation or other arrhythmias, heart block, heart wall or
vein wall rupture, hematoma/seroma, infection, myocardial irritability, myopotential sensing, pericardial effusion, pericardial rub,
pneumothorax, rejection phenomena, threshold elevation, thrombosis, thrombotic embolism, and valve damage.
See the device manual for detailed information regarding the implant procedure, indications, contraindications, warnings, precautions, and potential
complications/adverse events. For further information, please call Medtronic at 1-800-328-2518 and/or consult Medtronic’s website
at www.medtronic.com.
Caution: Federal law (USA) restricts this device to sale by or on the order of a physician.
Last updated:
01 Sep 2016
BRIEF STATEMENT (USA): MEDTRONIC CARELINK 2090
PROGRAMMER
The Medtronic CareLink programmer system is comprised of prescription devices indicated for use in the interrogation and
programming of implantable medical devices. Prior to use, refer to the Programmer Reference Guide as well as the appropriate
programmer software and implantable device technical manuals for more information related to specific implantable device
models. Programming should be attempted only by appropriately trained personnel after careful study of the technical manual
for the implantable device and after careful determination of appropriate parameter values based on the patient's condition and
pacing system used. The Medtronic CareLink programmer must be used only for programming implantable devices
manufactured by Medtronic or Vitatron.
See the device manuals for detailed information regarding the instructions for use, indications, contraindications, warnings,
precautions, and potential adverse events. For further information, please call Medtronic at 1-800-328-2518 and/or consult
Medtronic’s website at www.medtronic.com.
Caution: Federal law (USA) restricts this device to sale by or on the order of a physician.
medtronic.com
©2017 Medtronic.
Minneapolis, MN. All Rights Reserved.
January 2017